Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Gabay

Showing results (71-80 of 259) with videos related to

Pageof 26
Sort By:
The American Journal of Pathology|November 5, 2002
Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusionAtsushi Kato, Cem Gabay, Tomohisa Okaya, et al.
Joint Bone Spine|September 21, 2010
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonistsLaure Brulhart, Michael J Nissen, Paola Chevallier, et al.
The Journal of Investigative Dermatology|May 4, 2007
Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammationGaby Palmer, Dominique Talabot-Ayer, Gürkan Kaya, et al.
Plos One|October 4, 2017
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesisMaria Stella Lombardi, Corine Gilliéron, Majoska Berkelaar, et al.
Joint Bone Spine|March 18, 2009
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureNadia Announ, Gaby Palmer, Pierre-André Guerne, et al.
The Journal of Biological Chemistry|May 26, 2009
Interleukin-33 is biologically active independently of caspase-1 cleavageDominique Talabot-Ayer, Céline Lamacchia, Cem Gabay, et al.
Cytokine|July 18, 2015
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseasesJennifer Palomo, Damien Dietrich, Praxedis Martin, et al.
Annals of the Rheumatic Diseases|February 2, 2012
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsSophie Martin Du Pan, Almut Scherer, Cem Gabay, et al.
Frontiers in Immunology|July 23, 2013
The Activity of CCL18 is Principally Mediated through Interaction with GlycosaminoglycansSonja Krohn, Alexandre Garin, Cem Gabay, et al.
International Journal of Dermatology|July 30, 2019
Long-term therapy with anakinra in hidradenitis suppurativa in three patientsRaphaël André, Hélène Marescassier, Cem Gabay, et al.
Pageof 26

Showing results (71-80 of 259) with videos related to

Sort By:
Pageof 26
The American Journal of Pathology|November 5, 2002
Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusionAtsushi Kato, Cem Gabay, Tomohisa Okaya, et al.
Joint Bone Spine|September 21, 2010
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonistsLaure Brulhart, Michael J Nissen, Paola Chevallier, et al.
The Journal of Investigative Dermatology|May 4, 2007
Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammationGaby Palmer, Dominique Talabot-Ayer, Gürkan Kaya, et al.
Plos One|October 4, 2017
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesisMaria Stella Lombardi, Corine Gilliéron, Majoska Berkelaar, et al.
Joint Bone Spine|March 18, 2009
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureNadia Announ, Gaby Palmer, Pierre-André Guerne, et al.
The Journal of Biological Chemistry|May 26, 2009
Interleukin-33 is biologically active independently of caspase-1 cleavageDominique Talabot-Ayer, Céline Lamacchia, Cem Gabay, et al.
Cytokine|July 18, 2015
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseasesJennifer Palomo, Damien Dietrich, Praxedis Martin, et al.
Annals of the Rheumatic Diseases|February 2, 2012
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsSophie Martin Du Pan, Almut Scherer, Cem Gabay, et al.
Frontiers in Immunology|July 23, 2013
The Activity of CCL18 is Principally Mediated through Interaction with GlycosaminoglycansSonja Krohn, Alexandre Garin, Cem Gabay, et al.
International Journal of Dermatology|July 30, 2019
Long-term therapy with anakinra in hidradenitis suppurativa in three patientsRaphaël André, Hélène Marescassier, Cem Gabay, et al.
Pageof 26